stoxline Quote Chart Rank Option Currency Glossary
  
CNS Pharmaceuticals, Inc. (CNSP)
1.305  0.045 (3.57%)    07-12 14:19
Open: 1.19
High: 1.36
Volume: 845,946
  
Pre. Close: 1.26
Low: 1.17
Market Cap: 4(M)
Technical analysis
2024-07-12 1:50:10 PM
Short term     
Mid term     
Targets 6-month :  6.42 1-year :  9.67
Resists First :  5.49 Second :  8.27
Pivot price 1.55
Supports First :  1 Second :  0.83
MAs MA(5) :  1.15 MA(20) :  1.85
MA(100) :  10.62 MA(250) :  48.96
MACD MACD :  -1.5 Signal :  -1.7
%K %D K(14,3) :  6.6 D(3) :  3.8
RSI RSI(14): 27.8
52-week High :  137.5 Low :  1
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CNSP ] has closed above bottom band by 36.3%. Bollinger Bands are 69.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.65 - 1.66 1.66 - 1.67
Low: 1.1 - 1.1 1.1 - 1.11
Close: 1.25 - 1.26 1.26 - 1.27
Company Description

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Headline News

Tue, 09 Jul 2024
CNS Pharmaceuticals regains NASDAQ compliance - Investing.com

Mon, 08 Jul 2024
Cns Pharmaceuticals Inc (CNSP-Q) Quote - Press Release - The Globe and Mail

Wed, 03 Jul 2024
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement - Yahoo Finance

Wed, 26 Jun 2024
CNS Pharmaceuticals secures $1.39 million in funding - Investing.com

Wed, 26 Jun 2024
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement - StockTitan

Fri, 14 Jun 2024
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement - StockTitan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 1 (M)
Shares Float 0 (M)
Held by Insiders 1.3 (%)
Held by Institutions 1.3 (%)
Shares Short 63 (K)
Shares Short P.Month 1 (K)
Stock Financials
EPS -391
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -20.77
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -240.9 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -12.14
Qtrly Earnings Growth 0 %
Operating Cash Flow -13 (M)
Levered Free Cash Flow -7 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value -0.07
Price to Sales 0
Price to Cash Flow -0.15
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android